Search Results - "SHAYNE, Michelle"

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline by GRIGGS, Jennifer J, MANGU, Pamela B, SHAYNE, Michelle, SPARREBOOM, Alex, SUCHESTON, Lara E, LYMAN, Gary H, ANDERSON, Holly, BALABAN, Edward P, DIGNAM, James J, HRYNIUK, William M, MORRISON, Vicki A, MAY PINI, T, RUNOWICZ, Carolyn D, ROSNER, Gary L

“…To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. The American Society of Clinical Oncology…”
Get full text

Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy by Williams, AnnaLynn M., Shah, Raven, Shayne, Michelle, Huston, Alissa J., Krebs, Marcia, Murray, Nicole, Thompson, Bryan D., Doyle, Kassandra, Korotkin, Jenna, van Wijngaarden, Edwin, Hyland, Sharon, Moynihan, Jan A., Cory-Slechta, Deborah A., Janelsins, Michelle C.

“…Cancer-related cognitive impairment (CRCI) is often related to chemotherapy. Increased chronic inflammation is believed to play a key role in the development…”
Get full text

Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis by Vitek, Wendy S., M.D, Shayne, Michelle, M.D, Hoeger, Kathleen, M.D., M.P.H, Han, Yu, M.S, Messing, Susan, M.S, Fung, Chunkit, M.D., M.S

“…Objective To determine whether concurrent use of GnRH agonists with chemotherapy preserves ovarian function in women with breast cancer who did not use…”
Get full text

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy by Shayne, Michelle, Culakova, Eva, Poniewierski, Marek S., Wolff, Debra, Dale, David C., Crawford, Jeffrey, Lyman, Gary H.

“…BACKGROUND. This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer…”
Get full text

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26 by Turner, Bradley M., Gimenez‐Sanders, Mary Ann, Soukiazian, Armen, Breaux, Andrea C., Skinner, Kristin, Shayne, Michelle, Soukiazian, Nyrie, Ling, Marilyn, Hicks, David G.

“…The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A…”
Get full text

Second primary breast cancer after diagnosis of breast cancer among male patients: An examination of population characteristics and overall survival by Chowdhry, Amit K., Chowdhry, Divya N., Shayne, Michelle, Milano, Michael T.

“…Male patients with breast cancer (BrC) have increased risk of developing 2nd-primary BrC (2nd-BrC). Given the relative rarity of male BrC, population-based…”
Get full text

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease by Aivado, Manuel, Spentzos, Dimitrios, Germing, Ulrich, Alterovitz, Gil, Meng, Xiao-Ying, Grall, Franck, Giagounidis, Aristoteles A.N, Klement, Giannoula, Steidl, Ulrich, Otu, Hasan H, Czibere, Akos, Prall, Wolf C, Iking-Konert, Christof, Shayne, Michelle, Ramoni, Marco F, Gattermann, Norbert, Haas, Rainer, Mitsiades, Constantine S, Fung, Eric T, Libermann, Towia A

“…Myelodysplastic syndromes (MDS) are among the most frequent hematologic malignancies. Patients have a short survival and often progress to acute myeloid…”
Get full text

An Exploratory Study on the Effects of an Expectancy Manipulation on Chemotherapy-Related Nausea by Roscoe, Joseph A., PhD, O'Neill, Michael, MD, Jean-Pierre, Pascal, PhD, MPH, Heckler, Charles E., PhD, Kaptchuk, Ted J., OMD, Bushunow, Peter, MD, Shayne, Michelle, MD, Huston, Alissa, MD, Qazi, Raman, MD, Smith, Brian, MD

“…Abstract Context Previous research has shown that the effectiveness of acupressure bands in reducing chemotherapy-related nausea is related to patients'…”
Get full text

Prognosis by Shayne, Michelle

“…Shayne contends that the problem and the beauty of how this life is arranged is that there are certain things one is not meant to know with precision…”
Get full text

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update by Griggs, Jennifer J, Bohlke, Kari, Balaban, Edward P, Dignam, James J, Hall, Evan T, Harvey, R Donald, Hecht, Diane P, Klute, Kelsey A, Morrison, Vicki A, Pini, T May, Rosner, Gary L, Runowicz, Carolyn D, Shayne, Michelle, Sparreboom, Alex, Turner, Sophia, Zarwan, Corrine, Lyman, Gary H

“…To provide recommendations for appropriate dosing of systemic antineoplastic agents in obese adults with cancer. A systematic review of the literature…”
Get full text

Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity by Shayne, Michelle, Harvey, R. Donald, Lyman, Gary H.

“…A decrease in relative-dose intensity (RDI) of chemotherapy has been shown to be associated with poor patient outcomes in solid tumors and non-Hodgkin's…”
Get full text

Abstract P4-06-07: Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA) by Numbere, Numbereye, Moisini, Ioana, Dhakal, Ajay, Skinner, Kristin, Shayne, Michelle, Sanders, Mary Ann Gimenez, Zhang, Huina, Hicks, David, Turner, Bradley M

“…Abstract INTRODUCTION: In 2013, Klein and Dabbs et al. published three linear regression equations (the new Magee equations) using different combinations of…”
Get full text

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score by Turner, Bradley M, Skinner, Kristin A, Tang, Ping, Jackson, Mary C, Soukiazian, Nyrie, Shayne, Michelle, Huston, Alissa, Ling, Marilyn, Hicks, David G

“…Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain…”
Get full text

Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR) by Schaffer, Kerry, Kyi, Kaitlin, Lustig, Carol, Sahasrabudhe, Deepak M., Shayne, Michelle, Baran, Andrea M, Fung, Chunkit

“…Abstract only 322 Background: Germline and somatic HRR alterations are present in 12% and 20% of patients with mPC, respectively, and can have treatment…”
Get full text

A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes by Campbell, Thomas M., Campbell, Erin K., Culakova, Eva, Blanchard, Lisa M., Wixom, Nellie, Guido, Joseph J., Fetten, James, Huston, Alissa, Shayne, Michelle, Janelsins, Michelle C., Mustian, Karen M., Moore, Richard G., Peppone, Luke J.

“…Purpose Breast cancer treatment is associated with weight gain, and obesity and its related cardiometabolic and hormonal risk factors have been associated with…”
Get full text

A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes by Campbell, Erin K., Campbell, Thomas M., Culakova, Eva, Blanchard, Lisa, Wixom, Nellie, Guido, Joseph J., Fetten, James, Huston, Alissa, Shayne, Michelle, Janelsins, Michelle C., Mustian, Karen M., Moore, Richard G., Peppone, Luke J.

“…Purpose Quality of life (QOL) is among the most important outcomes for women with metastatic breast cancer (MBC), and it predicts survival. QOL is negatively…”
Get full text

Evidence table development as a novel teaching tool in cancer survivorship education by Shayne, Michelle, Culakova, Eva, Milano, Michael T., Constine, Louis S.

“…Abstract only 3 Background: We established a novel curriculum in Cancer Survivorship Education (CSE), as a collaborative effort between our accredited training…”
Get full text

Phase II study of exercise and low-dose ibuprofen for cancer-related cognitive impairment (CRCI) during chemotherapy by Janelsins, Michelle Christine, Shayne, Michelle, Huston, Alissa, Doyle, Kassandra, Culakova, Eva, Porto, Michelle, Lin, Po-Ju, Magnuson, Allison, Tejani, Mohamedtaki Abdulaziz, Dunne, Richard Francis, Dhakal, Ajay, Hezel, Aram F, Noel, Marcus Smith, Morrow, Gary R., Mohile, Supriya Gupta, Mustian, Karen Michelle

“…Abstract only 12016 Background: CRCI is a debilitating consequence of cancer and its treatment, including difficulties in attention, memory, and executive…”
Get full text

Abstract PS6-24: Are we missing something? Increased recurrence rates in patients with an oncotype DX score < 26 and a modified magee score > 18: A multi-institutional study by Turner, Bradley M, Gimenez-Sanders, Mary Ann, Moisini, Ioana, Zhang, Huina, Wang, Xi, Schiffhauer, Linda, Katerji, Hani, Skinner, Kristin, Gooch, Jessica, Shayne, Michelle, Ling, Marilyn, Falkson, Carla, Hicks, David

“…Abstract INTRODUCTION: Oncotype DX® (ODX) is a multigene assay estimating risk of distant recurrence and chemotherapy benefit in estrogen receptor (ER)…”
Get full text

Abstract PS6-18: Are we missing something? Ki-67 evaluation is important in African American women with an oncotype DX score< 26: A multi-institutional study by Turner, Bradley M, Gimenez-Sanders, Mary Ann, Zhang, Huina, Moisini, Ioana, Wang, Xi, Schiffhauer, Linda, Katerji, Hani, Skinner, Kristin, Gooch, Jessica, Shayne, Michelle, Ling, Marilyn, Falkson, Carla, Hicks, David

“…Abstract INTRODUCTION: The literature suggests that there is no difference in the Oncotype DX® (ODX) recurrence score between African American (AA) women and…”
Get full text